Jiangzhong Pharmaceutical and Hais Pharmaceutical successfully signed a strategic restructuring agreement

Source: People's Daily - Jiangxi Channel

On the morning of September 18, the strategic restructuring agreement between Jiangzhong Pharmaceutical and Haisi Pharmaceutical was successfully signed in Jiangzhong Medicine Valley. Lu Xiaoqing, Secretary of the Party Committee and General Manager of Crest Jiangzhong Pharmaceutical Group and Chairman of Jiangzhong Pharmaceutical, attended the signing ceremony.

Jiangzhong Pharmaceutical Strategic Restructuring Hayes Pharmaceutical Signing Ceremony Site. Photographed by Wang Dinghai

On behalf of CR Jiangzhong and Jiangzhong Pharmaceutical, Lu Xiaoqing extended a warm welcome to the leaders and guests, and introduced the development process, status quo and vision of Jiangzhong. Lu Xiaoqing said that Jiangzhong has been committed to the gastrointestinal health of the Chinese people for many years, focusing on the field of gastrointestinal daily medication, focusing on creating a fist product of "one intestine and one stomach", and has successively launched a series of consumer favorite brands such as Jiangzhong Jian Stomach Digestion Tablets, Jiangzhong Li Huo brand lactic acid bacteria tablets and Jiangzhong Li Huo brand probiotics. Hays Pharmaceutical adheres to the working idea of "production generation, reserve generation, development generation, and idea generation", relies on modern science and technology, carefully manufactures and ensures quality, and cultivates a number of products such as bifidobacterium tripartite enteric-coated capsules (Befida). The product planning of the two sides is compatible, and the realization of strategic cooperation will have good development prospects and broad cooperation space.

According to the agreement, Jiangzhong Pharmaceutical will reorganize the equity of Haisi Pharmaceutical by way of equity transfer and capital increase and share expansion, and obtain 51% of the equity of Haisi Pharmaceutical. After the completion of the strategic reorganization, Jiangzhong will give full play to its advantages in the OTC field, intelligent manufacturing, R&D and innovation, etc., to help Hayes Pharmaceutical expand OTC channel resources, achieve coordinated development, and create greater value for shareholders and society. (Li Xiaoyong)